Menü
Microsoft selbst warnt vor der Verwendung von Internet Explorer, da er nicht mehr den neuesten Web- und Sicherheitsstandards entspricht. Wir können daher nicht garantieren, dass die Seite im Internet Explorer in vollem Umfang funktioniert. Nutze bitte Chrome oder Firefox.

News und Analysen

Form 8.3 - The Vanguard Group, Inc.: Mediclinic International plc
Form 8.3 - The Vanguard Group, Inc.: Mediclinic International plc
Form 8.3 - The Vanguard Group, Inc.: Mediclinic International plc
Sartorius Stedim Biotech SA: DECLARATION RELATIVE TO THE NUMBER OF SHARES AND VOTING RIGHTS MAKING UP THE ISSUED CAPITAL
Sartorius Stedim Biotech SA: DECLARATION RELATIVE TO THE NUMBER OF SHARES AND VOTING RIGHTS MAKING UP THE ISSUED CAPITAL
Sartorius Stedim Biotech SA: DECLARATION RELATIVE TO THE NUMBER OF SHARES AND VOTING RIGHTS MAKING UP THE ISSUED CAPITAL
Poxel Announces Publication of Positive Phase 2 Results from Phase 2 NASH Trial (DESTINY-1) for PXL065 in Journal of Hepatology: https://mms.businesswire.com/media/20210929005940/en/578635/5/POXEL_LOGO_Q.jpg
Poxel Announces Publication of Positive Phase 2 Results from Phase 2 NASH Trial (DESTINY-1) for PXL065 in Journal of Hepatology


Regulatory News:



POXEL SA (Euronext : POXEL – FR0012432516), clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology

Sensorion to Participate in the 6th Annual Bioprocessing Summit Europe: https://mms.businesswire.com/media/20210609005851/en/705797/5/logo-sensorion2.jpg
Sensorion to Participate in the 6th Annual Bioprocessing Summit Europe


Regulatory News:



Sensorion (FR0012596468 – ALSEN) (Paris:ALSEN) a pioneering clinical-stage biotechnology company which specializes in gene therapies in the ear, is pleased to announce its

Savara to Present at the Oppenheimer 33rd Annual Healthcare Conference : https://mms.businesswire.com/media/20200730005071/en/747459/5/SavaraLogo.jpg
Savara to Present at the Oppenheimer 33rd Annual Healthcare Conference


Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that its management team will present at the Oppenheimer 33rd Annual

Aurinia Reports New Inducement Grants Under Nasdaq Listing Rule 5635(c)(4): https://mms.businesswire.com/media/20191107005278/en/707846/5/Aurinia-logo-web-700px.jpg
Aurinia Reports New Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)


Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (Aurinia or the Company), a biopharmaceutical company committed to delivering therapeutics that change the course of autoimmune, kidney and rare diseases

Agilent to Present at Barclays Global Healthcare Conference:
Agilent to Present at Barclays Global Healthcare Conference


Agilent Technologies Inc. (NYSE: A) today announced that Chief Financial Officer Bob McMahon will participate in a Q&A session at the Barclays Global Healthcare Conference in Miami Beach, Florida

Form 8.3 - The Vanguard Group, Inc.: Mediclinic International plc
Form 8.3 - The Vanguard Group, Inc.: Mediclinic International plc
Form 8.3 - The Vanguard Group, Inc.: Mediclinic International plc
Evolva partners with Grace Breeding to replace chemical fertilizers with nature-based alternative
Evolva partners with Grace Breeding to replace chemical fertilizers with nature-based alternative
Evolva partners with Grace Breeding to replace chemical fertilizers with nature-based alternative
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4): https://mms.businesswire.com/media/20191106005906/en/305625/5/puma_logo_JPEG.jpg
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)


Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that on March 1, 2023, the Compensation Committee of Puma’s Board of Directors approved the grant of an inducement

Form 8.3 - The Vanguard Group, Inc.: Mediclinic International plc
Form 8.3 - The Vanguard Group, Inc.: Mediclinic International plc
Form 8.3 - The Vanguard Group, Inc.: Mediclinic International plc
Form 8.3 - The Vanguard Group, Inc.: Jounce Therapeutics Inc
Form 8.3 - The Vanguard Group, Inc.: Jounce Therapeutics Inc
Form 8.3 - The Vanguard Group, Inc.: Jounce Therapeutics Inc
EQS-News: Eckert & Ziegler Submits Drug Master File for Lu-177 n.c.a.
EQS-News: Eckert & Ziegler Submits Drug Master File for Lu-177 n.c.a.
EQS-News: Eckert & Ziegler Submits Drug Master File for Lu-177 n.c.a.
Challenging business year 2022
Challenging business year 2022
Challenging business year 2022
Puma Biotechnology Reports Fourth Quarter and Full Year Financial Results: https://mms.businesswire.com/media/20191106005906/en/305625/5/puma_logo_JPEG.jpg
Puma Biotechnology Reports Fourth Quarter and Full Year Financial Results


Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced financial results for the fourth quarter and year ended December 31, 2022. Unless otherwise stated, all comparisons

QuidelOrtho to Participate in the Raymond James 44th Annual Institutional Investor Conference: https://s24.q4cdn.com/594651504/files/design/QO_Logo_FINAL.png
QuidelOrtho to Participate in the Raymond James 44th Annual Institutional Investor Conference


QuidelOrtho Corporation (Nasdaq: QDEL) (the “Company” or “QuidelOrtho”), a global provider of innovative in vitro diagnostics technologies designed for point-of-care settings, clinical labs and

Acadia Healthcare to Participate in March Investor Conferences: https://mms.businesswire.com/media/20200504005676/en/583255/5/ACHC.jpg
Acadia Healthcare to Participate in March Investor Conferences


Acadia Healthcare Company, Inc. (NASDAQ: ACHC) today announced that the Company will participate in two investor conferences in March.



On Tuesday, March 7, 2023, the Company will participate in

Humana and Aledade Announce 10 Year Collaboration: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/24514/Humana_logo.png
Humana and Aledade Announce 10 Year Collaboration


Aledade, the nation’s largest network of independent primary care, and Humana Inc. (NYSE: HUM), leading health insurer and health care services company, have announced a 10-year collaboration to

Vistagen to Present at Cowen 43rd Annual Health Care Conference: https://mms.businesswire.com/media/20220908005443/en/1564398/5/Vistagen_Primary-Logo_Blue.jpg
Vistagen to Present at Cowen 43rd Annual Health Care Conference


Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system

Silence Therapeutics to Report Fourth Quarter and Full Year 2022 Results on March 15, 2023: https://mms.businesswire.com/media/20220126005163/en/1338762/5/Silence-Logo-FINAL-rgb.jpg
Silence Therapeutics to Report Fourth Quarter and Full Year 2022 Results on March 15, 2023


Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the Company”), an experienced and innovative biotechnology company committed to transforming people’s lives by silencing diseases through

Form 8.3 - The Vanguard Group, Inc.: Mediclinic International plc
Form 8.3 - The Vanguard Group, Inc.: Mediclinic International plc
Form 8.3 - The Vanguard Group, Inc.: Mediclinic International plc
EQS-News: Sernova to Participate in Upcoming Roth and Oppenheimer Investor Conferences
EQS-News: Sernova to Participate in Upcoming Roth and Oppenheimer Investor Conferences
EQS-News: Sernova to Participate in Upcoming Roth and Oppenheimer Investor Conferences
Katya Kruglova to join Sonova’s Management Board as GVP Human Resources & Communications
Katya Kruglova to join Sonova’s Management Board as GVP Human Resources & Communications
Katya Kruglova to join Sonova’s Management Board as GVP Human Resources & Communications
Chemed Corporation to Present at the Oppenheimer 33rd Annual Healthcare Conference:
Chemed Corporation to Present at the Oppenheimer 33rd Annual Healthcare Conference


Chemed Corporation (NYSE:CHE) today announced that it will deliver a virtual presentation at the Oppenheimer 33rd Annual Healthcare Conference on Tuesday, March 14, 2023, at approximately 1:20 p.m

QIAGEN and SOPHiA GENETICS Forge Partnership to Combine Strengths in Next-Generation Sequencing
QIAGEN and SOPHiA GENETICS Forge Partnership to Combine Strengths in Next-Generation Sequencing


QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the launch of the new QIAseq Platform Partnership program and the first partnership with medical data-analysis provider